Wall Street brokerages expect that Ascendis Pharma A/S (NASDAQ:ASND) will post earnings per share of ($0.97) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Ascendis Pharma A/S’s earnings. The highest EPS estimate is ($0.28) and the lowest is ($1.38). Ascendis Pharma A/S reported earnings per share of ($1.31) in the same quarter last year, which suggests a positive year over year growth rate of 26%. The business is expected to issue its next quarterly earnings results on Wednesday, May 29th.
On average, analysts expect that Ascendis Pharma A/S will report full-year earnings of ($3.93) per share for the current year, with EPS estimates ranging from ($5.58) to ($0.42). For the next year, analysts forecast that the company will report earnings of ($3.58) per share, with EPS estimates ranging from ($6.81) to ($0.08). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.
Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.17) by $0.30. Ascendis Pharma A/S had a negative return on equity of 40.86% and a negative net margin of 1,275.08%. The firm had revenue of $12.00 million during the quarter.
ASND has been the subject of several analyst reports. Zacks Investment Research upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $82.00 target price for the company in a report on Friday, January 18th. Wedbush set a $217.00 target price on Ascendis Pharma A/S and gave the stock an “outperform” rating in a report on Thursday, March 7th. Evercore ISI initiated coverage on Ascendis Pharma A/S in a report on Monday, March 25th. They issued an “outperform” rating for the company. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. Finally, Credit Suisse Group reduced their target price on Ascendis Pharma A/S from $151.00 to $139.00 and set an “outperform” rating for the company in a report on Friday, March 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $135.56.
Several hedge funds have recently modified their holdings of ASND. Quantamental Technologies LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $25,000. Lindbrook Capital LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $54,000. SG Americas Securities LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $116,000. Financial Gravity Wealth Inc. acquired a new position in shares of Ascendis Pharma A/S during the first quarter worth approximately $128,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $204,000. Institutional investors own 95.46% of the company’s stock.
ASND traded up $0.64 on Friday, hitting $107.75. The company had a trading volume of 175,041 shares, compared to its average volume of 375,257. Ascendis Pharma A/S has a 1-year low of $53.21 and a 1-year high of $131.76. The firm has a market cap of $4.53 billion, a P/E ratio of -28.81 and a beta of 1.01.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Featured Article: The basics of gap trading strategies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.